• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 51
  • 40
  • 15
  • 5
  • 4
  • 3
  • 3
  • 2
  • Tagged with
  • 143
  • 30
  • 25
  • 20
  • 19
  • 16
  • 16
  • 16
  • 16
  • 14
  • 13
  • 12
  • 10
  • 10
  • 9
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

A study of in vitro drug resistance ofleukaemic cells from patients with acute lymphoblastic leukaemia

Maung, Zor T. January 1996 (has links)
No description available.
2

Development and application of enzyme-linked immunosorbent assays for the detection of drugs in the equine

Roberts, Caroline Jane January 1996 (has links)
No description available.
3

Lipocortins in the central nervous system in multiple sclerosis and experimental allergic encephalomyelitis

Elderfield, Amber-Jayne January 1994 (has links)
No description available.
4

Premature Rupture of Membranes: A Survey of the Current Clinical Practices of the Maternal-Fetal Medicine Obstetricians in the United States

Nwosu, Uchenna C., Thatcher, Samuel S. 01 January 1993 (has links)
To determine the current clinical practices of perinatologists regarding the management of premature rupture of membranes (PROM), 1,041 perinatologists were surveyed by multiple choice questionnaire with regard to induction of labor, use of antibiotics, tocolytic agents, and corticosteroids following uncomplicated PROM occurring between 19 and 36 weeks. The response rate was 51% (557/ 1,041). There was a consensus on expectant management of preterm PROM, except (1) where fetal lungs are found mature between 33 and 35 weeks gestation (51% induction vs. 44% expectant) and (2) at 19-22 weeks (71% undecided). During the expectant management the majority does not at any time use antibiotics, tocolytic agents, or corticosteroids. No uniform protocol has yet evolved for the management of preterm PROM, especially (1) between 33 and 35 weeks with mature fetal lungs, and (2) at 19-22 weeks gestation.
5

Optimising therapeutic strategies for chronic rhinosinusitis

Vaidyanathan, Sriram January 2014 (has links)
The aim of this thesis is to evaluate and optimise current pharmacotherapeutic options in rhinosinusitis. There is often a marked variation in treatment response in those afflicted with chronic rhinosinusitis, both within and between patients, attributable in part to different disease phenotypes/endotypes, poor awareness of treatment optimization options, and trivialization of symptoms by patients and physicians. Characteristically, these factors contribute to a typical remitting and relapsing disease course. The objectives of this work are to improve the therapeutic index and reach of commonly used medications by boosting efficacy whilst reducing concomitant side effects. The third chapter explores the use of initial oral steroids in patients with chronic rhinosinusitis and nasal polyposis, focusing on the role of the ostiomeatal complex in the perpetuation of disease symptoms. Often a short course of oral steroids is used in patients with moderate to severe disease to achieve initial control before maintenance with intranasal steroids. This is termed as a ‘medical polypectomy’ and anecdotally is commonly used in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). However, the evidence for its efficacy is tenuous and there are no data to evaluate if it indeed re-establishes ostiomeatal sinus complex drainage which is a condicio sine qua non of ensuring long-term symptom resolution. Further, it is known that monotherapy with nasal steroids may result in loss of symptom control. We have therefore in a double-blind placebo controlled trial (Chapter 4) evaluated the effect of this initial induction with oral steroids on subsequent sequential intranasal therapy. Perhaps, however, more crucially we have for the first time comprehensively addressed the safety of both oral and topical steroids in patients with CRSwNP who have other concomitant steroid-dependent illnesses like asthma and COPD. A particularly refractory subset of those with CRSwNP also have aspirin intolerance and asthma. While recent guidelines have recommended more aspirin challenge testing in these patients, it is unclear what the significance of a positive test is in the absence of overt clinical symptoms or in patients with only moderate disease. This is addressed in Chapter 5, as this significant phenotype of aspirin intolerant rhinosinusitis need close monitoring, dose optimization, polytherapy, and in selected cases may be suitable for aspirin desensitization. Penultimately, we evaluate in a double-blind placebo controlled trial (Chapter 6) the tachyphylaxis and rebound congestion that blights the medium to long-term use of sympathomimetic nasal decongestant sprays like oxymetazoline and if this can be reversed by the concomitant use of nasal steroids. We also characterized nasal blood flow as an outcome to evaluate in these patients and its relation to other rhinological outcome measures (Chapter 7).
6

Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic obstructive pulmonary disease and the impact of coexisting asthma

Goring, Sarah 11 1900 (has links)
Background: Chronic obstructive pulmonary disease (COPD) is a devastating illness that affects 4.3% of the population of British Columbia over the age of 45 years. Asthma is known to coexist in 10-20% of individuals with obstructive lung disease, and adds to the substantial burden of illness posed by COPD alone. Inhaled corticosteroids (ICS) are currently recommended for the management of COPD among individuals with frequent exacerbations; however, the ability of inhaled corticosteroids to reduce death and hospitalizations among individuals with COPD is controversial. Less is known about the effectiveness of ICS among individuals who are afflicted with both COPD and asthma. Methods: We used a retrospective cohort study design and administrative data to estimate the relative effectiveness of ICS in reducing hospitalizations or death among individuals with concomitant asthma and COPD, compared with individuals with COPD alone. We used an extended Cox model to estimate this association, with a time-varying measure of exposure to ICS. Results: We did not find any association between ICS and hazard of death or hospitalization among individuals with COPD alone (HR = 0.99; 95% CI: 0.94 – 1.05), however the hazard was 18% lower (HR = 0.82; 95% CI: 0.69-0.99) among individuals with concomitant disease. Conclusions: Individuals with combined COPD and asthma show significant benefit from the use of ICS and are more responsive to the effects of ICS than individuals with COPD alone.
7

The influence of inhaled corticosteroids on normal voice production in adults : an acoustic study

Sahrawat, Ramesh January 2010 (has links)
Corticosteroids are the most potent and reliable of the available agents among the anti-inflammatory drugs, and have assumed a major role in the management of asthma. This has subsequently resulted in the global widespread use of inhaled corticosteroids (ICS). A variety of studies have been undertaken to examine the effects of ICS on voice production among people with asthma. Most research suggests that the long-term use of ICS has a negative effect on voice production. However, the results of these studies are limited because of the reliance upon examining an asthmatic population and not consistently recording the dose prescribed. As a result, one cannot exclude that some of the voice problems may have been previously caused by asthma and thus, the contributing effects of ICS are obscured. Therefore, an ideal approach to examine the influence of ICS on voice is to test its short-term effects on healthy individuals, using a specific ICS (Fluticasone Propionate) at a fixed dose (1000 µg/Day). Thirty healthy adults (15 females & 15 males) aged between 18 to 30 years participated in this study. All participants were non-smokers with no history of speech, language or voice disorder. No participants had a history of asthma, respiratory illness hospital admission or inhaler use within the past 3 months. All participants followed the treatment regime often prescribed by physicians (in Canterbury region) for treating asthma (500 µg in morning & 500 µg in evening). Each participant self administered (inhaled) two puffs of ICS in the morning and again in the evening over a six day period. Voice samples were audio-recorded prior to undergoing the ICS regime, at various points during the ICS regime, and at the conclusion of ICS regime. Each participant’s audio-recorded samples were submitted for acoustic analysis using a commercially available speech analysis system (CSL 4300B, Kay Elemetrics, 1994). Three measures were performed, (1) vocal fundamental frequency (F0), (2) long-time spectral analysis (LTAS) and (3) formant frequency and formant frequency bandwidth. The results of this study indicate that ICS does have an effect on acoustic properties of voice. These effects were more evident in connected speech compared to isolated vowel productions. In particular, the spectral tilt and first spectral peak of continuous speech samples were found to change from baseline. The current results are discussed in regard to the phonatory deterioration associated with ICS use. The present study provides a framework for developing ICS treatment for respiratory disease in the phase of minimizing adverse effects on voice.
8

The effects of petroleum hydrocarbons on the early life stages of turbot

Stephens, Susan M. January 1997 (has links)
No description available.
9

Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic obstructive pulmonary disease and the impact of coexisting asthma

Goring, Sarah 11 1900 (has links)
Background: Chronic obstructive pulmonary disease (COPD) is a devastating illness that affects 4.3% of the population of British Columbia over the age of 45 years. Asthma is known to coexist in 10-20% of individuals with obstructive lung disease, and adds to the substantial burden of illness posed by COPD alone. Inhaled corticosteroids (ICS) are currently recommended for the management of COPD among individuals with frequent exacerbations; however, the ability of inhaled corticosteroids to reduce death and hospitalizations among individuals with COPD is controversial. Less is known about the effectiveness of ICS among individuals who are afflicted with both COPD and asthma. Methods: We used a retrospective cohort study design and administrative data to estimate the relative effectiveness of ICS in reducing hospitalizations or death among individuals with concomitant asthma and COPD, compared with individuals with COPD alone. We used an extended Cox model to estimate this association, with a time-varying measure of exposure to ICS. Results: We did not find any association between ICS and hazard of death or hospitalization among individuals with COPD alone (HR = 0.99; 95% CI: 0.94 – 1.05), however the hazard was 18% lower (HR = 0.82; 95% CI: 0.69-0.99) among individuals with concomitant disease. Conclusions: Individuals with combined COPD and asthma show significant benefit from the use of ICS and are more responsive to the effects of ICS than individuals with COPD alone.
10

Padronizacao da tecnica de medida do cortisol no plasma humano por competicao a proteina fixadora (transcortina)

OKADA, HELENA 09 October 2014 (has links)
Made available in DSpace on 2014-10-09T12:24:01Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:07:55Z (GMT). No. of bitstreams: 1 00481.pdf: 828758 bytes, checksum: 1c5f5457d167dcdae526c01f18297ab6 (MD5) / Dissertacao (Mestrado) / IEA/D / Instituto de Biociencias, Universidade de Sao Paulo - IB/USP

Page generated in 0.112 seconds